CVS aims to avoid hyperinflated drugs

More than 3,400 drugs saw price hikes in the first half of 2019, with the average increase being more than five times the rate of inflation, according to CVS Caremark.

And part of the rapid rise of price spikes is due to hyperinflated medications, particularly among “me-too” therapies that cost way more but are actually similar to alternatives already on the market that cost less.

One such example is a muscle relaxant Chlorzoxane, which costs an average of $2,903 for a 30-day supply. The average cost of its alternative, cyclobenzaprine, is just $1.76 for the same supply. CVS has continued to remove drugs that were significantly higher priced from its template formulary.

CVS Caremark, the pharmacy branch of CVS Health, noted these changes as it announced how the company kept price growth to 3.1% while drug price inflation ballooned 25% in 2018. The company did so in part by removing hyperinflation drugs, as well as staying on top of suspected fraud, waste and abuse, and specialty guideline management.

“Introduced in 2017, this strategy was designed to help blunt the impact of drugs with significant inflation from one year to the next,” reads a brief from CVS Caremark.

The brief comes at a time when drug prices continue to rise in 2019 and have become the focus of ire for the Trump administration.

The company reviews its strategy on an ongoing basis, rather than annually, to continue removing hyperinflated therapies when there are cheaper alternatives available. Once these drugs were removed from template formularies, CVS saw a 99% drop in utilization of them, the brief found. The project client savings were $4.60 per year, or $0.38 per month.

“Helping clients contain costs, ensuring appropriate utilization, and rooting out wasteful and inefficient spend, while also keeping medications affordable for members, remains a focus for us,” the company said.

The savings add up––Clients with the template formularies with drug removals spent $88.30 on average per 30-day supply compared to those on formularies without drug removals, who spent $102.58 on average in 2018. Net prescription drug prices dropped for 44% of clients last year.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”